This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Waterloo directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $100,000
Improvements in quality of life, health utility, cost, and return to work for lymphoma patients after chimeric antigen receptor T- cells therapy in a real-world setting
CIHR · 2021 · Principal investigator
- $100,000
Understanding the treatment benefits of chimeric antigen receptor T-cells for lymphoma: quality of life, health utility, cost, and return to work
CIHR · 2020 · Co-investigator
Improvements in quality of life, health utility, cost, and return to work for lymphoma patients after chimeric antigen receptor T- cells therapy in a real-world setting
Principal investigators: Wong, William Wai Lun; Chan, Kelvin K; Prica, Anca
Keywords: Chimeric Antigen Receptor T-Cells; Cost-Effectiveness Analysis; Health Utility; Out-Of-Pocket Costs; Quality Of Life; Time Costs
Understanding the treatment benefits of chimeric antigen receptor T-cells for lymphoma: quality of life, health utility, cost, and return to work
Principal investigators: Wong, William Wai Lun; Chan, Kelvin K
Keywords: Chimeric Antigen Receptor T-Cells; Cost-Effectiveness Analysis; Health Utility; Out-Of-Pocket Costs; Quality Of Life; Time Costs
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.